Focal Prostate Ablation Versus Radical Prostatectomy

NCT ID: NCT03668652

Last Updated: 2025-04-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

213 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-30

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to compare the treatment results of HIFU and Radical prostatectomy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The FARP randomized control study will compare focal ablation of prostate using High Intensity Focused Ultrasound (HIFU) applied by FocalOne® or TULSA® device versus Radical Prostatectomy (RP) in patients with unilateral, intermediate risk prostate cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized controlled trial.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Focal treatment of prostate cancer using HIFU compared to Radical prostatectomy.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Focal prostate cancer treatment by HIFU

Patients with target lesion distance \< 30 mm from the rectum will be treated with High Intensity Focused Ultrasound (HIFU) applied by FocalOne HIFU device and patients with lesion localized \> 30 mm from the rectum will be treated with TULSA applied by TULSA-PRO device.

Group Type EXPERIMENTAL

Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical)

Intervention Type DEVICE

HIFU arm:

Focal ablation of prostate cancer using HIFU Focal One or TULSA -PRO

Radical Prostatectomy

Robot assisted laparoscopic radical prostatectomy or open retro-pubic radical prostatectomy will be performed using validated radical prostatectomy technique. Nerve sparing surgery on side of cancer free prostate lobe will be performed and type of nerve sparing procedure will be specified.

Group Type ACTIVE_COMPARATOR

Radical prostatectomy

Intervention Type PROCEDURE

Prostatectomy arm:

Robot assisted or open retropubic prostatectomy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical)

HIFU arm:

Focal ablation of prostate cancer using HIFU Focal One or TULSA -PRO

Intervention Type DEVICE

Radical prostatectomy

Prostatectomy arm:

Robot assisted or open retropubic prostatectomy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Positive MRI (PIRAD 3-5) and biopsy proven unilateral prostate cancer classified as ISUP 1 (with cancer core length \> 5mm) or ISUP 2-3 (any length) not eligible to active surveillance or watchful waiting
* PSA ≤ 20 ng/ml
* Treatment naive patients with localized prostate cancer (stage ≤ T2b)

Exclusion Criteria

* Clinical stage T\> 2b
* Metastatic lymph node on imaging
* Patients already treated for Pca (hormone therapy, EBRT)
* Patients with contra-indications to MRI
* Patients with active inflammatory bowel disease or previous rectal fistula
* History of previous pelvic radiotherapy
* History of bladder cancer
* History of bladder neck or urethral stricture
* Urogenital infection in progress
* Allergy to latex or gadolinium
* Patients on life support or suffering form unstable neurological diseases
Minimum Eligible Age

45 Years

Maximum Eligible Age

80 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Oslo

OTHER

Sponsor Role collaborator

Oslo University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Eduard Baco

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eduard Baco, MD, PhD, Prof. assoc.

Role: PRINCIPAL_INVESTIGATOR

Department of Cancer Surgery, Oslo University Hospital, Radiumhospitalet

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Cancer surgery, Oslo University Hospital, Radiumhospitalet

Oslo, , Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017/703

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.